|
Malignant neoplasm of ovary
|
0.900 |
Biomarker
|
disease |
BEFREE |
Collectively, our results suggested for the first time that NGF is functionally linked to β-catenin in the migration of human ovarian cancer cells, which may be a novel therapeutic perspective to prevent the spread of ovarian carcinomas by studying the interaction between NGF/NGFRs and canonical WNT/β-catenin signaling.
|
27835587 |
2016 |
|
Malignant neoplasm of ovary
|
0.900 |
Biomarker
|
disease |
BEFREE |
Our study identifies activated Wnt signalling to be a marker for precursor lesions of OC and successfully develops a mouse model that mimics the earliest events in pathogenesis of OC by constitutively activating βcatenin.
|
27588493 |
2016 |
|
ovarian neoplasm
|
0.900 |
Biomarker
|
disease |
BEFREE |
Thus, β-catenin could be a potential therapeutic target for the therapy of cisplatin-resistant ovarian cancer.
|
25211326 |
2015 |
|
ovarian neoplasm
|
0.900 |
Biomarker
|
disease |
BEFREE |
β-Catenin knockdown blocked tumor growth and peritoneal metastasis in an OC xenograft model.
|
24954508 |
2015 |
|
Malignant neoplasm of ovary
|
0.900 |
Biomarker
|
disease |
BEFREE |
β-Catenin knockdown blocked tumor growth and peritoneal metastasis in an OC xenograft model.
|
24954508 |
2015 |
|
Malignant neoplasm of ovary
|
0.900 |
Biomarker
|
disease |
BEFREE |
Thus, β-catenin could be a potential therapeutic target for the therapy of cisplatin-resistant ovarian cancer.
|
25211326 |
2015 |
|
ovarian neoplasm
|
0.900 |
GeneticVariation
|
disease |
CLINVAR |
Prospective enterprise-level molecular genotyping of a cohort of cancer patients.
|
25157968 |
2014 |
|
ovarian neoplasm
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
We studied nine single nucleotide polymorphisms (SNPs) located in CTNNB1 (β-catenin) [rs4533622, rs2953], APC (rs11954856, rs351771, rs459552), and AXIN2 (rs4074947, rs7224837, rs3923087, rs2240308) in women with ovarian cancer without BRCA1/BRCA2 mutations (n = 228) and controls (n = 282).
|
24078348 |
2014 |
|
Malignant neoplasm of ovary
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
We studied nine single nucleotide polymorphisms (SNPs) located in CTNNB1 (β-catenin) [rs4533622, rs2953], APC (rs11954856, rs351771, rs459552), and AXIN2 (rs4074947, rs7224837, rs3923087, rs2240308) in women with ovarian cancer without BRCA1/BRCA2 mutations (n = 228) and controls (n = 282).
|
24078348 |
2014 |
|
ovarian neoplasm
|
0.900 |
Biomarker
|
disease |
BEFREE |
Collectively, these data indicated that β-catenin is involved in Twist2-induced EMT in ovarian cancer.
|
24244294 |
2013 |
|
Malignant neoplasm of ovary
|
0.900 |
Biomarker
|
disease |
BEFREE |
Collectively, these data indicated that β-catenin is involved in Twist2-induced EMT in ovarian cancer.
|
24244294 |
2013 |
|
ovarian neoplasm
|
0.900 |
Biomarker
|
disease |
BEFREE |
WNT7A regulates tumor growth and progression in ovarian cancer through the WNT/β-catenin pathway.
|
22232518 |
2012 |
|
Malignant neoplasm of ovary
|
0.900 |
Biomarker
|
disease |
BEFREE |
WNT7A regulates tumor growth and progression in ovarian cancer through the WNT/β-catenin pathway.
|
22232518 |
2012 |
|
ovarian neoplasm
|
0.900 |
Biomarker
|
disease |
CTD_human |
Effect of downregulated β-catenin on cell proliferative activity, the sensitivity to chemotherapy drug and tumorigenicity of ovarian cancer cells.
|
22000491 |
2011 |
|
ovarian neoplasm
|
0.900 |
Biomarker
|
disease |
BEFREE |
CXC chemokine receptor 4 plays a critical role in the metastasis of human ovarian cancer possibly through modulating the Wnt/β-catenin pathway.
|
21738044 |
2011 |
|
Malignant neoplasm of ovary
|
0.900 |
Biomarker
|
disease |
BEFREE |
CXC chemokine receptor 4 plays a critical role in the metastasis of human ovarian cancer possibly through modulating the Wnt/β-catenin pathway.
|
21738044 |
2011 |
|
Malignant neoplasm of ovary
|
0.900 |
Biomarker
|
disease |
CTD_human |
Effect of downregulated β-catenin on cell proliferative activity, the sensitivity to chemotherapy drug and tumorigenicity of ovarian cancer cells.
|
22000491 |
2011 |
|
ovarian neoplasm
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Oncogenic activation of the Wnt signaling pathway is common in cancers, but mutation of beta-catenin in ovarian cancer is rare.
|
19957335 |
2010 |
|
Malignant neoplasm of ovary
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Oncogenic activation of the Wnt signaling pathway is common in cancers, but mutation of beta-catenin in ovarian cancer is rare.
|
19957335 |
2010 |
|
ovarian neoplasm
|
0.900 |
Biomarker
|
disease |
BEFREE |
Tissue microarray analysis of human FRAT1 expression and its correlation with the subcellular localisation of beta-catenin in ovarian tumours.
|
16479254 |
2006 |
|
ovarian neoplasm
|
0.900 |
AlteredExpression
|
disease |
BEFREE |
beta-catenin expression, DNA ploidy and clinicopathological features in ovarian cancer: a study in 253 patients.
|
15911235 |
2005 |
|
ovarian neoplasm
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
Nuclear immunoreactivities for beta -catenin and CTNNB1 mutations were restricted to independent uterine and ovarian tumors and were absent in all of the metastatic tumors, providing direct evidence for a divergence of molecular oncogenetic mechanisms in the subset of synchronous endometrioid carcinomas.
|
16021566 |
2005 |
|
Malignant neoplasm of ovary
|
0.900 |
AlteredExpression
|
disease |
BEFREE |
In this study, the impact of beta-catenin expression on genomic instability in ovarian carcinoma, as determined by DNA ploidy, was investigated.
|
15911235 |
2005 |
|
ovarian neoplasm
|
0.900 |
GeneticVariation
|
disease |
BEFREE |
In search of this transformation mechanism in human cancer cells, we identified breast and ovarian tumor lines with upregulation of the uncomplexed transcriptionally active form of beta-catenin without mutations afflicting downstream components.
|
15542433 |
2004 |
|
ovarian neoplasm
|
0.900 |
AlteredExpression
|
disease |
BEFREE |
In addition, we have determined that the cadherin-associated protein, known as beta-catenin, is expressed in normal peritoneum, ovarian tumors and malignant cell effusions obtained from women with Stage I or Stage II cancer.
|
12800191 |
2003 |